New to the Huntington's Disease Lighthouse?
 Welcome to the HDlighthouse!
 Getting started.
 
Home \ Research \ Clinical Trials \ Updates
Predict-HD: Recruiting Gene Negative Individuals

Posted to the HDL: 02 Oct 2006


Predict-HD: Recruiting Gene Negative Individuals

The PREDICT-HD Research Team at the University of Iowa

The PREDICT-HD study is currently recruiting gene negative individuals! Thanks to the HDLighthouse website posting of the recent PREDICT-HD journal article and Will Brown�s wonderful participation article, we have started to receive inquiries from interested individuals wanting to become involved in our important research study. Below we have included an additional study description along with contact information about how to become one of our valuable participants.

Thank you for your interest and consideration!

Background and Study Aims

Huntington�s Disease (HD) is an inherited disease that causes changes in a person�s ability to control movements, thinking, and feelings. The intent of this study is to learn more about the beginning changes in thinking skills, emotional regulation, and brain structure and function as a person begins the transition from health to HD.

Preliminary studies indicate that people with HD may have marked decline before an actual diagnosis. This study will help reveal the earliest indicators of the disease and what factors influence the age at which a person carrying the gene develops the disease. It is necessary to get information on the early stages of HD in order to develop drugs that can slow or postpone the onset of HD. The investigators hope this study will provide essential information for future trials of experimental drugs for HD.

During this study, participants will undergo several detailed tests, including MRI scans of the brain, cognitive assessments, physical exams, and neurological and psychiatric testing.

Eligibility:Inclusion Criteria

  • Gene negative individuals: specifically, men and women at risk for HD, who have been tested for the HD gene mutation (CAG <30 for CAG-norm group).
  • 18 years of age or older
  • Able to commit to a minimum of 4 yearly evaluations
  • Commitment of a companion to attend visits or complete surveys via mail
  • Able to undergo a MRI

For More Information about Participating

Please contact one of the University of Iowa�s PREDICT-HD recruitment team members who can assist in facilitating enrollment at one of our 32 research sites:

Or visit the PREDICT-HD Link on the Huntington Study Group website: http://www.huntington-study-group.org/ for a full list of participating sites and contact information or call the HSG toll-free at 800-487-7671.

# # #

Source:

print this
printer friendly
version

 

Read the HDAC/HDLighthouse Forum. Post your comments
   
Related Topics
Research focusing on the formation of aggregates caused by HD
 
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
 
Research related HD and it's general affect on the brain
 
Research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease.
 
Research focusing on gene therapy.
 
Research focusing on gene transcription.
 
General research related to HD
 
Research studying the genetics of Huntington's Disease
 
Research studying the Immune System and it's effect on the progression of HD
 
Research studying the brain tissue and research related to stem cells
 
Recent Updates
18 Jul 2008
Participants needed for qualitative studies of JHD
The University of Iowa is recruiting participants for two important new studies.
 
9 Jun 2008
The Research Pipeline - taking drugs from the lab to the clinic
Here's an overview of some of the more promising potential treatments moving through the research pipeline.
 
12 Mar 2008
Phase III creatine trial
NCCAM and the Orphan Product Division of the FDA is funding a phase III clinical trial of medicinal grade creatine.
 
1 Oct 2007
ACR16 closer to Phase III clinical trials
Neurosearch applies for permission to start Phase III clinical trials of ACR16, a dopamine stabilizer, in Europe and the U.S.
 
30 Sep 2007
Research Study for those At Risk
Last call for participants in an At Risk study.
 
19 Aug 2007
Riluzole Found Ineffective for Huntington's Disease Patients
A Phase III clinical trial of the glutamate blocker riluzole failed to slow progression or improve symptoms in HD patients.
 
1 Aug 2007
Daniel P. Van Kammen, MD, Phd, to lead CHDI Huntington's Disease Clinical Development Effort
MRSSI, Inc. announced today that Daniel P. van Kammen MD, PhD has joined as Chief Medical Officer.
 
31 Jul 2007
HD Study for Those At Risk
John Hopkins University and the National Human Genome Research Institute are starting a new study for those at risk.
 
28 Jul 2007
HSG to Conduct a Phase 2 Study in Adults with Mild-to-Moderate Huntington Disease
HSG announces a Phase II study of Dimebon
 
5 Feb 2007
Miraxion Study Completed, Results Soon
Amarin Corp. and the HSG have completed a Phase III clinical trial of Miraxion which investigated whether the drug improves motor symptoms in HD.
 

All Updates for Clinical Trials
Disclaimer & Privacy Policy | Welcome | Site Feedback Marsha@HDLighthouse.org